AI Generated
Apr 15, 2026, 16:55
Chokri Ben Lamine: VA-ECMO vs VV-ECMO Thromboembolic Events – Key Clinical Pearls
Chokri Ben Lamine, Adult Hematology and SCT Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital and Research Center, shared a post on X:
“VA-ECMO vs VV-ECMO Thromboembolic Events – Key Clinical Pearls
Credits: Dr Hazzaa Alzahrani – KFSHRC
VA-ECMO equals Cardiac plus Respiratory support – higher overall thrombotic risk
VV-ECMO equals Respiratory only – high risk but mainly venous/circuit-related
Risk profile
- VA-ECMO – high arterial plus venous thrombosis (shock, low flow, arterial cannulation)
- VV-ECMO – predominantly venous plus circuit thrombosis (less arterial)
Thrombotic pattern
- VA – arterial embolism, stroke, limb ischemia, intracardiac thrombus
- VV – oxygenator clot, circuit thrombosis, cannula-related DVT, VTE
Incidence
- VA – ~17% thrombotic complications (meta-analysis)
- VV – up to ~40% reported (mostly circuit-related)
Limb ischemia
- VA – COMMON (10–30%) due to arterial cannulation major complication
- VV – RARE (no arterial access)
Stroke / systemic embolism
- VA – HIGH risk – thrombus forms in heart/aorta – embolizes systemically
- VV – LOWER – mainly venous events, less arterial embolism
Intracardiac thrombosis
- VA – typical (LV stasis, poor ejection, inadequate unloading)
- VV – NOT typical
Cannula-associated DVT (post-decannulation)
- VV – COMMON, often underdiagnosed
- VA – occurs but less emphasized
Why different?
- VA – shock, low pulsatility, arterial cannulation, LV stasis, endothelial injury
- VV – large venous cannulas, long runs, inflammation, hemolysis, circuit shear stress
Clinical takeaway
- VA-ECMO equals arterial plus embolic complications dominate – stroke and limb ischemia vigilance
- VV-ECMO equals venous/circuit thrombosis dominate – DVT and oxygenator monitoring”
More posts featuring Chokri Ben Lamine on Hemostasis Today.
-
May 27, 2026, 04:47Daniel Torrent: The Overlooked Epidemic of Post-Thrombotic Syndrome
-
May 27, 2026, 04:45Graziella Pompei: Is Aspirin Still a Valid Alternative to Clopidogrel in PCI with DES Implantation?
-
May 27, 2026, 04:40Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
-
May 27, 2026, 04:29Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
-
May 27, 2026, 04:14Michael R. Jaff: HI-PEITHO Trial and NEWS Score Insights on Advances for Intermediate-Risk Pulmonary Embolism
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK
-
May 26, 2026, 16:40Hamed Helisaz: Machine Learning for Detecting Missing Heart Medications
-
May 26, 2026, 15:32Haroun Gajraj: Brown Marks After Microsclerotherapy – What Every Practitioner Needs to Know
-
May 26, 2026, 15:29Jacqueline van Paassen: Lack of Essential Clinical Data in DOAC Prescriptions in Community Pharmacies